Literature DB >> 8285610

Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis.

T F Patterson1, A W Fothergill, M G Rinaldi.   

Abstract

The efficacy of an itraconazole-cyclodextrin solution against Aspergillus fumigatus was assessed in an immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis and compared with that of amphotericin B. Oral itraconazole solution at dosages of 20 and 40 mg/kg/day improved survival as compared with that of controls. Itraconazole (40 mg/kg/day) not only improved survival and reduced antigen levels but also significantly eradicated A. fumigatus from tissues and was as effective as amphotericin B in these studies. The higher dose of itraconazole produced higher levels in serum, which correlated with improved efficacy of the drug. This itraconazole-cyclodextrin solution was well absorbed and was effective in the treatment of experimental invasive aspergillosis; it demonstrates the potential of this class of agents in improving therapy for invasive aspergillosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8285610      PMCID: PMC192383          DOI: 10.1128/AAC.37.11.2307

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice.

Authors:  A Polak
Journal:  Chemotherapy       Date:  1987       Impact factor: 2.544

Review 2.  Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

Authors:  D W Denning; D A Stevens
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

3.  In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents.

Authors:  D W Denning; L H Hanson; A M Perlman; D A Stevens
Journal:  Diagn Microbiol Infect Dis       Date:  1992-01       Impact factor: 2.803

4.  Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model.

Authors:  T F Patterson; P Miniter; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

Review 5.  Aspergillosis.

Authors:  G P Bodey; S Vartivarian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

Review 6.  New antifungal agents.

Authors:  J R Graybill
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

7.  Treatment of invasive aspergillosis with itraconazole.

Authors:  D W Denning; R M Tucker; L H Hanson; D A Stevens
Journal:  Am J Med       Date:  1989-06       Impact factor: 4.965

8.  The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen.

Authors:  J R Sabetta; P Miniter; V T Andriole
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

9.  Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.

Authors:  T F Patterson; P Miniter; J Dijkstra; F C Szoka; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

10.  The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis.

Authors:  T F Patterson; D George; P Miniter; V T Andriole
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

View more
  9 in total

1.  Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Systemic availability of itraconazole in lung transplantation.

Authors:  T F Patterson; J Peters; S M Levine; A Anzueto; C L Bryan; E Y Sako; O L Miller; J H Calhoon; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; D Loebenberg; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis.

Authors:  William R Kirkpatrick; Ana C Vallor; Robert K McAtee; Neil S Ryder; Annette W Fothergill; Michael G Rinaldi; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 5.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

6.  Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis.

Authors:  J Roberts; K Schock; S Marino; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

7.  Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Authors:  William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Inhibition of Candida albicans in vivo and in vitro by antimicrobial peptides chromogranin A-N12 through microRNA-155/suppressor of cytokine signaling 1 axis.

Authors:  Xiaohua Li; Qun Hu; Qiong Lin; Jianxiong Luo; Junping Xu; Lifang Chen; Liyu Xu; Xin Lin
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

9.  Down-regulation of microRNA-155 suppressed Candida albicans induced acute lung injury by activating SOCS1 and inhibiting inflammation response.

Authors:  Xiaohua Li; Yuanzhong Gong; Xin Lin; Qiong Lin; Jianxiong Luo; Tianxing Yu; Junping Xu; Lifang Chen; Liyu Xu; Ying Hu
Journal:  J Microbiol       Date:  2022-02-14       Impact factor: 2.902

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.